




## B cells




## T cells




## Naive T cells




## Treg cells




## NK cells




## Macrophages




## Dendritic cells



## Fibroblasts




## Progenitors





**Supplemental Figure S1.** The canonical marker genes expression for cell-type annotation of cells from the patient's subcutaneous lesion, related to Figure 2A-B.

**A**


# Visualization of the skin lesion cell-types and activities

**B**



## The Most Enriched GO Terms in Malignant GEP

**C**


**Supplemental Figure S2. Identification of activity programs and identity programs in the tumor tissue. (A)** UMAP plots of cells colored by maximum identity GEP usage (left) or by absolute usage of each activity GEP (right). Int, identity; DC, dendritic cells; NK, nature killer cells; B, B cells; Epi, epithelial cells; Endo, endothelia cells; Fibro, fibroblasts; SPTCL, Subcutaneous panniculitis-like T-cell lymphoma; T, T cells; Macro, macrophages; Mus, muscle. **(B)** Bar plots of P-values for the top 10 Gene Ontology geneset enrichments for the identity and activity GEPs. **(C)** Heatmap summarizing mean expression (normalized and log-transformed) of Int.SPTCL markers in each cluster. The gene expression value has been scaled for visualizations. The covariate bar on the top side indicates the component associated with each gene.




**Supplemental Figure S3.** UMAP projection of donors' samples with normal CD8<sup>+</sup> T cells (n=13,494) and patient sample with CD8<sup>+</sup> cells (n=5,956) in subcutaneous lesion tissue, related to Figure 2. BM, bone marrow; LG, lung; LN, lymph node; PB, peripheral blood; resting; SL, subcutaneous lesion; CD3<sup>+</sup> T cells isolated from tissues and blood were cultured in media alone; activated, in the presence of anti-CD3/anti-CD28 antibodies.



**Supplemental Figure S4. Integrative genomics view of the *HAVCR2* genotype with whole-exome sequencing in the patient's subcutaneous lesion tissue.** The result showed that there was no coding mutation existed in the *HAVCR2* gene, except for a common coding SNP (p.R140L, rs1036119) with allele frequency 0.9893 in East Asian population based on the genome aggregation database (gnomAD v2.1.1).




**Supplemental Figure S5. UMAP embedding of three gene expression (*HAVCR2*, *TNF*, *IL2*, *CXCL10*, *IL18*, *IL2RA*).** The results showed that the SPTCL malignant cells with no mutations of *HAVCR2* had regular expression of *HAVCR2* and *CXCL10* and low expression of *TNF*, *IL2*, *IL18*, and *IL2RA* compared with normal T cells.




**Supplemental Figure S6.** Dot plots show gene expression of *CD4* and *FOXP3* for the *CD4*<sup>+</sup> T cells of the subcutaneous lesion sample of the SPTCL patient studied. *CD4*<sup>+</sup>*FOXP3*<sup>+</sup> T cells were colored in red, *CD4*<sup>+</sup>*FOXP3*<sup>-</sup> T cells were colored in blue. We calculated the percentage (21.97%) of *CD4*<sup>+</sup>*FOXP3*<sup>+</sup> T cells in *CD4*<sup>+</sup> T cells to estimate the proportion of Tregs in subcutaneous lesion.

## Integration of SL-CD8<sup>+</sup> and donors' normal CD8<sup>+</sup> cells




**Supplemental Figure S7.** Integration UMAP projects of known markers used to diagnose SPTCL. SL, subcutaneous lesion.




**Supplemental Figure S8. Transcriptomic comparison of CD8<sup>+</sup> T cells from the patient peripheral blood, bone marrow, tumor tissue, related to Figure 3. (A)** UMAP projection of patient sample with normal CD8<sup>+</sup> T cells outlined in grey and malignant CD8<sup>+</sup> cells in orange. BM, bone marrow; PB, peripheral blood; SL, subcutaneous lesion. **(B)** Cells are colored with various clustering by the Leiden algorithm. Results of partition-based graph abstraction (PAGA).


# Integration of SL-CD8<sup>+</sup> cells and matched PB/BM CD8<sup>+</sup> cells




**Supplemental Figure S9.** Results of known markers and GEP-program cell scores in UMAP space (first two dimensions). BM, bone marrow; PB, peripheral blood; SL, subcutaneous lesion.



Supplemental Figure S10. Violin plots of known markers of SPTCL (adjusted  $P < 1e-10$ ).



Supplemental Figure S11. Violin plots showing previously identified gene expression of SPTCL cells (adjusted  $P < 1e-10$ ).



**Supplemental Figure S12. Verification results of three novel markers (VCAM1, CXCL13, TIMD4).** (A) Immunohistochemical stain from subcutaneous lesion biopsies of Subcutaneous panniculitic-like T-cell lymphoma (SPTCL, n=1), and panniculitis (PA, n=3), each at 20x (left) and 40x (right).